Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584516 | 1.00 | KCNH2 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL29589035 | 1.00 | KCNH2 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL539875 | 1.00 | KCNH2 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL1280052 | 1.00 | KCNH2 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL29588998 | 1.00 | KCNH2 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL7980093 | 0.98 | KCNH2 (0.45) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL546303 | 0.93 | EGLN1 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL7943555 | 0.93 | EGLN1 (0.46) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL3998414 | 0.92 | EGLN1 (0.44) | KCNH2EGLN1OPRK1OPRM1OPRD1 | |
| SCHEMBL20369603 | 0.85 | SCN3A (0.48) | KCNH2OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11753446-B2 | Beta-hairpin peptidomimetics | POLYPHOR AG (CH) | 2023-09-12 | — | — | US | disclosed |
| EP-1268525-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6486174-B2 | TREATMENT OF TUMOR GROWTH, METASTASIS, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, SICKLE CELL ANEMIA, NERVE SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION | 2002-08-08 | — | — | US | disclosed |
| US-20020061885-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020037897-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002012193-A1 | TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID ALKOXYGUANIDINES AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-6323215-B1 | TREAT AND PREVENT DISORDERS CHARACTERIZED BY NEURONAL DAMAGE SUCH AS PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, STROKE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, DIABETIC NEUROPATHY AND BELL'S PALSY. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | disclosed |
| WO-2001077113-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORPORATION (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001004090-A2 | NEUROTROPHIC TETRAHYDROISOQUINOLINES AND TETRAHYDROTHIENOPYRIDINES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-1998016526-A1 | TETRAHYDRO-6H-PYRAZINO[1,2-B]ISOQUINOLINE 1,4-DIONES AS APOPROTEIN B-100 INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | KCNH2 1749/4885EGLN1 816/4885OPRK1 85/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | KCNH2 4870/4885EGLN1 1697/4885OPRK1 3675/4885 |
| US-20020037897-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | ADGRE5, ITGAL, VCAM1 | KCNH2 508/4885EGLN1 4024/4885OPRK1 201/4885 |
| US-20020061885-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | ITGAL, ITGAV, ITGB3 | KCNH2 167/4885EGLN1 4050/4885OPRK1 29/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | KCNH2 4869/4885EGLN1 1586/4885OPRK1 3614/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | KCNH2 4049/4885EGLN1 1934/4885OPRK1 3058/4885 |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | HPN, TMPRSS15, HAVCR2 | KCNH2 4082/4885EGLN1 3655/4885OPRK1 2742/4885 |
| US-11753446-B2 | Beta-hairpin peptidomimetics | POLL, BACE1, C1S | KCNH2 816/4885EGLN1 4475/4885OPRK1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.